Cell News and Research

RSS

Sigma-Aldrich unveils new Sigma Life Science brand and website platform

Sigma-Aldrich® today unveiled its new Sigma® Life Science brand and website platform, designed to elevate the Company's current focus on biology and provide a single destination where researchers can access deep biological knowledge and market-leading products and technologies.

2 Mar 2010

Simvastatin impairs ability of macrophages to kill pathogens, and enhances cytokine production

Simvastatin might help us control our cholesterol, but when it comes to infection, it's an entirely different story says a new research study published in the Journal of Leukocyte Biology. In the research report, scientists from Italy show that simvastatin delivers a one-two punch to the immune system. First it impairs the ability of specialized immune cells, called macrophages, to kill pathogens. Then, it enhances production of molecules, called cytokines, which trigger and sustain inflammation.

2 Mar 2010

News outlets examine development of low-cost diagnostic tool, infectious disease surveillance

CNN examines the work of a Harvard University chemistry professor to "shrink a medical laboratory onto a piece of paper that's the size of a fingerprint and costs about a penny." According to George Whitesides, who created a prototype of the inexpensive paper "chip," the technology could be used to diagnose such diseases as HIV, malaria and tuberculosis in developing countries.

2 Mar 2010

New class of breast cancer: Overexpression of LRP6 gene could be a potential marker

A newly identified cancer biomarker could define a new subtype of breast cancer as well as offer a potential way to treat it, say researchers at Washington University School of Medicine in St. Louis. Their findings will be published in the March 1 online early edition issue of the Proceedings of the National Academy of Sciences.

2 Mar 2010

BioSante Pharmaceuticals announces receipt of two US patents directed to 2A/Furin technology

BioSante Pharmaceuticals, Inc. today announced the receipt of two US patents directed to its 2A/Furin technology for expressing proteins. The first issued US patent, US Pat. No., 7,632,059, covers methods for manufacturing recombinant antibodies.

2 Mar 2010

febit releases updated Geniom Biochip containing 58 new miRNA sequences

febit today announced that an updated version of the company's Geniom Biochip containing 58 new discovered sequences in addition to all of the Homo sapiens microRNAs (miRNA) from miRBase version 14 is now available for cancer research. The 58 new miRNA sequences were found by deep sequencing in a miRNA discovery study performed on an Applied Biosystems SOLiD 3 sequencing system. All 58 miRNAs have been validated using the ABI TaqMan miRNA qRT-PCR assay and are now available for further studies using febit's microarray technology for miRNA-profiling.

2 Mar 2010

GTC Biotherapeutics achieves high-level production of TG20 monoclonal antibody

GTC Biotherapeutics, Inc. announced that it has achieved high-level production of TG20; an anti-CD20 monoclonal antibody (MAb). The TG20 MAb, which is produced in the milk of transgenic goats, is being co-developed by GTC and LFB as part of the LFB-GTC joint venture.

2 Mar 2010

Gene research offers new hope for targeted breast cancer treatment

CANCER RESEARCH UK scientists have developed a system to identify faulty or missing genes that could prevent specific chemotherapy regimes from working. This opens the doors for targeted breast cancer treatment, according to research published in the Lancet Oncology* today (Monday).

2 Mar 2010

NovoStent receives CE Mark for SAMBA Stent and Delivery System for treatment of PAD

NovoStent® Corporation, a privately held medical device company, today announced that it has received CE Mark for its SAMBATM Stent and Delivery System for the treatment of peripheral artery disease. The SAMBA Stent was designed to treat the highly varied presentation of atherosclerotic disease in the superficial femoral (SFA) and popliteal arteries by providing a unique combination of strength, flexibility and vessel coverage.

2 Mar 2010

Researchers develop sensitive measuring system for cGVHD

Researchers from The University of Texas M. D. Anderson Cancer Center have developed a new assessment tool to measure the severity of symptoms that can complicate stem cell transplantation. The tool assesses symptoms resulting from chronic graft-versus-host disease (cGVHD), and was presented with supporting research at the 2010 Bone and Marrow Transplant Tandem Meeting.

2 Mar 2010

Oxidative stress could lead to health problems and premature death

If you aren't getting a good, consistent and regular night's sleep, a new study suggests it could reduce your ability to handle oxidative stress, cause impacts to your health, increase motor and neurological deterioration, speed aging and ultimately cut short your life.

2 Mar 2010

FDA's ODAC to review CTI's pixantrone NDA on March 22, 2010

Cell Therapeutics, Inc. announced today that the U.S. Food and Drug Administration's ("FDA") Oncologic Drugs Advisory Committee ("ODAC") will review CTI's New Drug Application ("NDA") for pixantrone for the treatment of relapsed/refractory aggressive non-Hodgkin's lymphoma ("NHL") on March 22, 2010.

2 Mar 2010

New treatment guidelines demonstrate that best care does not always cost more

Arizona Oncology is proud to be a part of the larger network that just completed a recently conducted study by US Oncology and Aetna that finds evidence-based care for patients with non-small cell lung cancer (NSCLC) results in an average cost savings of 35 percent over 12 months while demonstrating equivalent health outcomes.

2 Mar 2010

Researchers proceed to develop vaccination to reverse neurological damage seen with Parkinson's disease

Researchers at the University of Nebraska Medical Center have taken a significant step forward in developing a vaccination approach to reverse the neurological damage seen with Parkinson's disease.

2 Mar 2010

ARIAD Pharmaceuticals' investigational pan-BCR-ABL inhibitor receives FDA and EMA orphan drug designation

ARIAD Pharmaceuticals, Inc. today announced that its investigational pan-BCR-ABL inhibitor, AP24534, has been granted orphan drug designation by both the U. S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). In the U.S., the orphan designation of AP24534 is for the treatment of chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) and in the E.U., its orphan designation is for CML and acute lymphoblastic leukemia.

2 Mar 2010

Quark Pharmaceuticals commences dosing in clinical study of QPI-1007 for NAION

Quark Pharmaceuticals, Inc., a world leader in the discovery and development of RNAi-based therapeutics, announced today the dosing of the first patient in a Phase I study of the investigational neuroprotective agent, QPI-1007.

2 Mar 2010

AnaptysBio announces strategic collaboration to generate novel antibodies for specified disease target

AnaptysBio, Inc., a privately-held therapeutic antibody platform and product company, today announced a strategic collaboration with an undisclosed leading global pharmaceutical company to generate novel antibody therapeutics to a specified disease target. This is the third collaboration with a leading pharmaceutical company announced by AnaptysBio during 2010.

1 Mar 2010

Scopolamine drug: A rapid-acting antidepressant for depression symptoms

Conventional antidepressant treatments generally require three to four weeks to become effective, thus the discovery of treatments with a more rapid onset is a major goal of biological psychiatry. The first drug found to produce rapid improvement in mood was the NMDA glutamate receptor antagonist, ketamine.

1 Mar 2010

COMP issues positive opinion for Æterna Zentaris' perifosine orphan medicinal product designation

Æterna Zentaris Inc., a late-stage drug development company specialized in oncology and endocrinology, today announced that it has received a positive opinion for orphan medicinal product designation for its compound perifosine from the Committee for Orphan Medicinal Products (COMP) of the European Medicines Agency, for the treatment of multiple myeloma.

1 Mar 2010

Peer-reviewed articles elucidate role of clusterin in promoting tumor resistance to cancer treatment

OncoGenex Pharmaceuticals, Inc., announced today that two peer-reviewed articles have been published that further elucidate the biological function of clusterin, its role in promoting tumor resistance to cancer treatment, and the role of an inhibitor of clusterin such as custirsen (OGX-011) that is designed to knock down treatment resistance in the cells and enhance the effectiveness of cancer therapies.

1 Mar 2010

Cell News and Research

Sigma-Aldrich unveils new Sigma Life Science brand and website platform

Simvastatin impairs ability of macrophages to kill pathogens, and enhances cytokine production

News outlets examine development of low-cost diagnostic tool, infectious disease surveillance

New class of breast cancer: Overexpression of LRP6 gene could be a potential marker

BioSante Pharmaceuticals announces receipt of two US patents directed to 2A/Furin technology

febit releases updated Geniom Biochip containing 58 new miRNA sequences

GTC Biotherapeutics achieves high-level production of TG20 monoclonal antibody

Gene research offers new hope for targeted breast cancer treatment

NovoStent receives CE Mark for SAMBA Stent and Delivery System for treatment of PAD

Researchers develop sensitive measuring system for cGVHD

Oxidative stress could lead to health problems and premature death

FDA's ODAC to review CTI's pixantrone NDA on March 22, 2010

New treatment guidelines demonstrate that best care does not always cost more

Researchers proceed to develop vaccination to reverse neurological damage seen with Parkinson's disease

ARIAD Pharmaceuticals' investigational pan-BCR-ABL inhibitor receives FDA and EMA orphan drug designation

Quark Pharmaceuticals commences dosing in clinical study of QPI-1007 for NAION

AnaptysBio announces strategic collaboration to generate novel antibodies for specified disease target

Scopolamine drug: A rapid-acting antidepressant for depression symptoms

COMP issues positive opinion for Æterna Zentaris' perifosine orphan medicinal product designation

Peer-reviewed articles elucidate role of clusterin in promoting tumor resistance to cancer treatment

Discover how SciY empowers scientists

Why use light scattering to analyze proteins and viral vectors?

Changing the landscape of R&D to build clinical success from the ground up

Latest Life Science News